Notably, in vitro treatment of IBD mucosal immune cells with Cay10591, a specific SIRT1 activator, reduces NF-κB activation and inhibits the production of inflammatory cytokines, as well as Cay10591 prevents and cures IBD-like colitis in mice (51). Here, SIRT1 is linked to inflammatory bowel disease.